AU2018348429B2 - Multispecific antibody - Google Patents

Multispecific antibody

Info

Publication number
AU2018348429B2
AU2018348429B2 AU2018348429A AU2018348429A AU2018348429B2 AU 2018348429 B2 AU2018348429 B2 AU 2018348429B2 AU 2018348429 A AU2018348429 A AU 2018348429A AU 2018348429 A AU2018348429 A AU 2018348429A AU 2018348429 B2 AU2018348429 B2 AU 2018348429B2
Authority
AU
Australia
Prior art keywords
seq
nos
amino acid
pdl1
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018348429A
Other languages
English (en)
Other versions
AU2018348429A1 (en
Inventor
Matthias Brock
Tea Gunde
Christian Hess
Sebastian Meyer
Alexandre Simonin
David Urech
Stefan Warmuth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Numab Therapeutics AG
Original Assignee
Numab Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP17195779.8A external-priority patent/EP3470426A1/en
Application filed by Numab Therapeutics AG filed Critical Numab Therapeutics AG
Publication of AU2018348429A1 publication Critical patent/AU2018348429A1/en
Application granted granted Critical
Publication of AU2018348429B2 publication Critical patent/AU2018348429B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2018348429A 2017-10-10 2018-10-09 Multispecific antibody Active AU2018348429B2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP17195779.8 2017-10-10
EP17195779.8A EP3470426A1 (en) 2017-10-10 2017-10-10 Multispecific antibody
EP18150465 2018-01-05
EP18150465.5 2018-01-05
EP18167093.6 2018-04-12
EP18167093 2018-04-12
EP18180814 2018-06-29
EP18180814.8 2018-06-29
PCT/EP2018/077509 WO2019072868A1 (en) 2017-10-10 2018-10-09 MULTISPECIFIC ANTIBODIES

Publications (2)

Publication Number Publication Date
AU2018348429A1 AU2018348429A1 (en) 2020-03-12
AU2018348429B2 true AU2018348429B2 (en) 2025-08-28

Family

ID=63799025

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018348429A Active AU2018348429B2 (en) 2017-10-10 2018-10-09 Multispecific antibody

Country Status (16)

Country Link
US (1) US12202911B2 (enExample)
EP (1) EP3694873A1 (enExample)
JP (1) JP7442443B2 (enExample)
CN (1) CN111194323B (enExample)
AU (1) AU2018348429B2 (enExample)
BR (1) BR112020006999A2 (enExample)
CA (1) CA3075969A1 (enExample)
CL (2) CL2020000937A1 (enExample)
CO (1) CO2020003882A2 (enExample)
IL (1) IL273576A (enExample)
MA (1) MA50352A (enExample)
MX (1) MX2020003562A (enExample)
PE (1) PE20200849A1 (enExample)
SG (1) SG11202002982YA (enExample)
WO (1) WO2019072868A1 (enExample)
ZA (1) ZA202001294B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11459394B2 (en) 2017-02-24 2022-10-04 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
US11365240B2 (en) * 2017-06-05 2022-06-21 Numab Therapeutics AG Anti-HSA antibodies
CN111183159B (zh) * 2017-10-10 2024-09-03 努玛治疗有限公司 靶向cd137的抗体及其使用方法
AU2018363292A1 (en) * 2017-11-13 2020-05-21 Crescendo Biologics Limited Molecules that bind to CD137 and PSMA
TWI839395B (zh) * 2018-10-09 2024-04-21 瑞士商Ｎｕｍａｂ治療公司 靶向cd137的抗體及其使用方法
WO2021013142A1 (zh) * 2019-07-22 2021-01-28 江苏恒瑞医药股份有限公司 抗4-1bb抗体、其抗原结合片段及双特异性抗体
CN117586400A (zh) 2019-10-11 2024-02-23 南京维立志博生物科技有限公司 结合4-1bb的抗体及其用途
EP3816185A1 (en) * 2019-11-04 2021-05-05 Numab Therapeutics AG Multispecific antibody directed against pd-l1 and a tumor-associated antigen
MX2022008214A (es) * 2020-01-09 2022-08-08 Hoffmann La Roche Nuevas moleculas de union al antigeno que contienen el trimero de 4-1bbl.
EP4153316A1 (en) 2020-05-19 2023-03-29 Boehringer Ingelheim International GmbH Binding molecules for the treatment of cancer
CA3184899A1 (en) * 2020-05-29 2021-12-02 Numab Therapeutics AG Multispecific antibody
CN114195900B (zh) * 2020-09-17 2024-02-23 普米斯生物技术(珠海)有限公司 一种抗4-1bb/pd-l1双特异性抗体及其用途
EP3988568A1 (en) 2020-10-21 2022-04-27 Numab Therapeutics AG Combination treatment
WO2022136693A1 (en) 2020-12-23 2022-06-30 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
EP4373848A2 (en) 2021-07-22 2024-05-29 University of Dundee Therapeutic muteins
EP4519309A1 (en) 2022-05-06 2025-03-12 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
EP4273162A1 (en) 2022-05-06 2023-11-08 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
AU2024275787A1 (en) 2023-05-19 2025-11-27 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
WO2025133389A1 (en) 2023-12-22 2025-06-26 Numab Therapeutics AG Antibody binding domains having specificity for lilrb2

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016149201A2 (en) * 2015-03-13 2016-09-22 Cytomx Therapeutics, Inc. Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
WO2017123650A2 (en) * 2016-01-11 2017-07-20 Inhibrx Lp Multivalent and multispecific 41bb-binding fusion proteins

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
JPS60500673A (ja) 1983-03-08 1985-05-09 コモンウエルス　セラム　ラボラトリ−ズ　コミツシヨン 抗原活性を有するアミノ酸配列
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
ATE120761T1 (de) 1987-05-21 1995-04-15 Creative Biomolecules Inc Multifunktionelle proteine mit vorbestimmter zielsetzung.
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US6267964B1 (en) 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
EP1291360A1 (en) 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
WO2001045746A2 (en) 1999-12-24 2001-06-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
JP4336771B2 (ja) 2001-03-09 2009-09-30 モルフォシス アーゲー 血清アルブミン結合部分
US20030157561A1 (en) * 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
EP1576172A2 (en) 2002-06-21 2005-09-21 Dyax Corporation Serum protein-associated target-specific ligands and identification method therefor
EP2135879A3 (en) 2002-06-28 2010-06-23 Domantis Limited Ligand
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
WO2004010947A2 (en) 2002-07-30 2004-02-05 Bristol-Myers Squibb Company Humanized antibodies against human 4-1bb
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
AU2003301882A1 (en) 2002-11-01 2004-06-07 The Regents Of The University Of Colorado, A Body Corporate Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry
EA012622B1 (ru) 2004-06-01 2009-10-30 Домэнтис Лимитед Биспецифичные гибридные антитела с увеличенным периодом полувыведения из сыворотки
KR20070094909A (ko) 2004-12-02 2007-09-27 도만티스 리미티드 혈청 알부민 및 ｇｌｐ-1 또는 ｐｙｙ를 표적으로 삼는이중특이성 도메인을 갖는 항체
RS54271B1 (sr) 2005-07-01 2016-02-29 E. R. Squibb & Sons, L.L.C. Humana monoklonska antitela za ligand programirane smrti 1 (pd-l1)
ES2627223T3 (es) 2007-06-26 2017-07-27 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H Presentación de agentes de unión
CA2700714C (en) 2007-09-26 2018-09-11 Ucb Pharma S.A. Dual specificity antibody fusions
CA2737241C (en) 2008-09-26 2017-08-29 Ucb Pharma S.A. Multivalent antibody fusion proteins
HRP20170908T1 (hr) 2008-12-09 2017-09-22 F. Hoffmann - La Roche Ag Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice
EA201270174A1 (ru) 2009-07-16 2012-07-30 Глэксо Груп Лимитед Отдельные связывающиеся вариабельные домены с улучшенными свойствами, направленные против сывороточного альбумина
PT2504364T (pt) 2009-11-24 2017-11-14 Medimmune Ltd Agentes de ligação direcionados contra b7-h1
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
PH12020550156A1 (en) 2010-09-09 2024-01-15 Pfizer 4-1bb binding molecules
RS61033B1 (sr) 2011-11-28 2020-12-31 Merck Patent Gmbh Antitela na pd-l1 i njihova upotreba
MA41044A (fr) * 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
KR102689285B1 (ko) * 2014-11-26 2024-07-31 젠코어 인코포레이티드 Ｃｄ3 및 종양 항원과 결합하는 이종이량체 항체
JP2018508509A (ja) * 2015-02-22 2018-03-29 ソレント・セラピューティクス・インコーポレイテッド Ｃｄ１３７に結合する抗体医薬
WO2016202457A1 (en) 2015-06-15 2016-12-22 Numab Ag Hetero-dimeric multi-specific antibody format
WO2017102835A1 (en) * 2015-12-14 2017-06-22 Complix Nv Binding molecule comprising an alphabody-polypeptide and an antibody
CN111183159B (zh) 2017-10-10 2024-09-03 努玛治疗有限公司 靶向cd137的抗体及其使用方法
SG11202001654TA (en) 2017-10-10 2020-03-30 Numab Therapeutics AG Antibodies targeting pdl1 and methods of use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016149201A2 (en) * 2015-03-13 2016-09-22 Cytomx Therapeutics, Inc. Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
WO2017123650A2 (en) * 2016-01-11 2017-07-20 Inhibrx Lp Multivalent and multispecific 41bb-binding fusion proteins

Also Published As

Publication number Publication date
US20230192897A1 (en) 2023-06-22
ZA202001294B (en) 2024-08-28
SG11202002982YA (en) 2020-04-29
US12202911B2 (en) 2025-01-21
CO2020003882A2 (es) 2020-05-29
MX2020003562A (es) 2020-10-01
KR20200063155A (ko) 2020-06-04
EP3694873A1 (en) 2020-08-19
AU2018348429A1 (en) 2020-03-12
CL2021000028A1 (es) 2021-05-28
IL273576A (en) 2020-05-31
WO2019072868A1 (en) 2019-04-18
CL2020000937A1 (es) 2020-09-25
CN111194323A (zh) 2020-05-22
CN111194323B (zh) 2024-07-09
JP7442443B2 (ja) 2024-03-04
JP2021501744A (ja) 2021-01-21
BR112020006999A2 (pt) 2020-10-06
PE20200849A1 (es) 2020-08-20
MA50352A (fr) 2020-08-19
CA3075969A1 (en) 2019-04-18

Similar Documents

Publication Publication Date Title
AU2018348429B2 (en) Multispecific antibody
AU2018348431B2 (en) Antibodies targeting CD137 and methods of use thereof
EP3470426A1 (en) Multispecific antibody
EP3470428A1 (en) Antibodies targeting cd137 and methods of use thereof
AU2018348430B2 (en) Antibodies targeting PDL1 and methods of use thereof
EP3470429A1 (en) Antibodies targeting pdl1 and methods of use thereof
JP2025020172A (ja) Ｃｄ１３７を標的とする抗体およびその使用方法
EP3636320A1 (en) Antibodies targeting cd137 and methods of use thereof
KR102907331B1 (ko) 다중 특이적 항체
KR102907326B1 (ko) Cd137을 표적화하는 항체 및 이의 사용 방법
EA047248B1 (ru) Мультиспецифическое антитело